Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: An immunohistochemical study in comparison with epithelioid pleural mesothelioma

Tumori

Volumn 100, Issue 5, 2014, Pages 559-567

  Comin, Camilla E ^a   Novelli, Luca ^a   Cavazza, Alberto ^b   Rotellini, Matteo ^a   Cianchi, Fabio ^a   Messerini, Luca ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Differential diagnosis; Epithelioid mesothelioma; Immunohisto chemistry; Primary lung carcinoma

Indexed keywords

CALRETININ; CYTOKERATIN 5; CYTOKERATIN 6; MONOCLONAL ANTIBODY D2-40; THROMBOMODULIN; WT1 PROTEIN; CALB2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PDPN PROTEIN, HUMAN; THBD PROTEIN, HUMAN; TUMOR MARKER; WT1 PROTEIN, HUMAN;

ARTICLE; CARCINOID; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EPITHELIOID PLEURA MESOTHELIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PLEURA MESOTHELIOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SARCOMATOID CARCINOMA; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CANCER; TISSUE DISTRIBUTION; TUMOR BIOPSY; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; COMPARATIVE STUDY; IMMUNOLOGY; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; PLEURAL NEOPLASMS;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CALBINDIN 2; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; NEOPLASMS, GLANDULAR AND EPITHELIAL; PLEURAL NEOPLASMS; THROMBOMODULIN; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 84916927913     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Husain AN, Colby TV, Ordoñez NG, 1. Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR: Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med, 133: 1317-1331, 2009.
2. King JE, Thatcher N, Pickering CA, Hasleton P: Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology, 48: 223-232, 2006.
3. Klebe S, Nurminen M, Leigh J, Henderson DW: Diagnosis of epithelial mesothelioma using three-based regression analysis and a minimal panel of antibodies. Pathology, 41: 140-148, 2009.
4. Ordoñez NG: What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol, 38: 1-16, 2007.
5. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC: World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. IARC press, Lyon, 2004.
6. Kao SC, Griggs K, Lee K, Armstrong N, Clarke S, Vardy J, van Zandwijk N, Burn J, McCaughan BC, Henderson DW, Klebe S: Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology, 43: 313-317, 2011.
7. Dittman WA, Majerus PW: Structure and function of thrombomodulin: A natural anticoagulant. Blood, 75: 329-336, 1990.
8. Ordoñez NG: Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology, 31: 25-30, 1997.
9. Ordoñez NG: Immunohistochemical diagnosis of epithelioid mesotheliomas: A critical review of old markers, new markers. Hum Pathol, 33: 953-967, 2002.
10. Collins CL, Ordoñez NG, Shaefer R, Cook CD, Xie SS, Granger J, Hsu PL, Fink L, Hsu SM: Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol, 141: 827-833, 1992.
11. Comin CE, Novelli L, Boddi V, Paglierani M, Dini S: Calretinin, thrombomodulin, CEA, and CD15: A useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol, 32: 529-536, 2001.
12. Comin CE, Dini S, Novelli L, Santi R, Asirelli G, Messerini L: h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Am J Surg Pathol, 30: 463-469, 2006.
13. Tolnay E, Wiethege T, Müller K-M: Expression and localization of thrombomodulin in preneoplastic bronchial lesions and in lung cancer. Virchows Arch, 430: 209-212, 1997.
14. Miettinen M, Sarlomo-Rikala M: Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types. An immunohistochemical analysis of 596 tumors in comparison with epithelioid mesothelioma of the pleura. Am J Surg Pathol, 27: 150-158, 2003.
15. Attanoos RL, Gibbs AR: 'Pseudomesotheliomatous' carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Histopathology, 43: 444-452, 2003.
16. Attanoos RL, Dojcinov SD, Webb R, Gibbs AR: Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology, 37: 224-231, 2000.
17. Lucas DR, Pass HI, Madan SK, Adsay NV, Wali A, Tabaczka P, Lonardo F: Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology, 42: 270-279, 2003.
18. Takeshima Y, Amatya VJ, Kushitani K, Kaneko M, Inai K: Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Histopathology, 54: 667-676, 2009.
19. Doglioni C, Dei Tos AP, Laurino L, Iuzzolino 19. P, Chiarelli C, Celio MR, Viale G: Calretinin: a novel immunocytochemical marker of mesothelioma. Am J Surg Pathol, 20: 1037-1046, 1996.
20. Lugli A, Forster Y, Haas P, Nocito A, Bucher C, Bissig H, Mirlacher M, Storz M, Mihatsch MJ, Sauter G: Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol, 34: 994-1000, 2003.
21. Ordoñez NG: Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol, 11: 929-933, 1998.
22. Pritchard SA, Howat AJ, Edwards JM: Immunohistochemical panel for distinction between squamous cell carcinoma, adenocarcinoma and mesothelioma. Histopathology, 43: 196-205, 2003.
23. Ordoñez NG: The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol, 19: 417-428, 2006.
24. Padgett DM, Cathro HP, Wick MR, Mills SE: Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol, 32: 123-127, 2008
25. Kenmotsu H, Ishii G, Nagai K, Nakao M, Kawase A, Kojika M, Murata Y, Nishiwaki Y, Ochiai A: Pleomorphic carcinoma of the lung expressing podoplanin and calretinin. Pathol Int, 58: 771-774, 2008.
26. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K: Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int, 58: 75-83, 2008.
27. Chu PG, Weiss LM: Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol, 15: 6-10, 2002.
28. Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE: The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol, 121: 235-247, 1985.
29. Moll R, Dhouailly D, Sun TT: Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas: An immunohistochemical study using monoclonal antibody AE14. Virchows Arch B, 58: 129-145, 1989.
30. Clover J, Oates J, Edwards C: Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology, 31: 140-143, 1997.
31. Ordoñez NG: Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol, 22: 1215-1221, 1998.
32. Watterwald A, Hofstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H, Atkinson M: Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone, 18: 125-132, 1996.
33. Kalof AN, Cooper K: D2-40 immunohistochemistry - so far! Adv Anat Pathol, 16: 62-64, 2009.
34. Ordoñez NG: D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid mesothelioma. Hum Pathol, 36: 372-380, 2005.
35. Ordoñez NG: Podoplanin: A novel diagnostic immunohistochemical marker. Adv Anat Pathol, 13: 83-88, 2006.
36. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ: Utility of D2-novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol, 18: 105-110, 2005.
37. Deniz H, Kibar Y, Güldür ME, Güldür ME, Bakir K: Is D2-useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract, 205: 749-752, 2009.
38. Mimura T, Ito A, Sakuma T, Ohbayashi C, Yoshimura M, Tsubota N, Okita Y, Okada M: Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesotelioma. Cancer, 109: 933-938, 2007.
39. Müller AM, Franke FE, Müller KM: D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Pathobiology, 73: 50-54, 2006.
40. Sienko A, Zander D, Killen D, Singhal N, Barrios R, Haque A, Cagle PT: D2-40 is a novel new marker of malignant mesothelioma (MM): tissue microarray study of versus 409 lung carcinomas and primary non-mesothelial neoplasms of the pleura and chest wall [Abstract]. Mod Pathol, 18 (suppl 1): 318, 2005.
41. Hu Y, Yang Q, McMahon LA, Wang HL, Xu H: Value of D2-the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor. Appl Immunohistochem Mol Morphol, 18: 411-413, 2010.
42. Hwang H, Quenneville L, Yaziji H, Gown AM: Wilms' tumor gene product. Sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol, 12: 122-126, 2004.
43. Sharnhorst V, Van der Eb AJ, Jochemsen AG: WT1 proteins: functions in growth and differentiation. Gene, 273: 141-161, 2001.
44. Tsuta K, Kato Y, Tochigi N, Hoshino T, Takeda Y, Hosako M, Maeshima AM, Asamura H, Kondo T, Matsuno Y: Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesotelioma. Appl Immunohistochem Mol Morphol, 17: 126-130, 2009.
45. Amin KM, Litzky LA, Smythe WR, Mooney AM, Morris JM, Mews DJ, Pass HI, Kari C, Rodeck U, Rauscher FJ 3rd. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol, 146: 344-356, 1995.
46. Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J, Van Broeckhoven C, Van Marck E: WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol, 181: 67-74, 1997.
47. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, Yao M, Takahashi E, Nakano Y, Hirabayashi H, Shintani Y, Oka Y, Tsuboi A, Hosen N, Asada M, Fujioka T, Murakami M, Kanato K, Motomura M, Kim EH, Kawakami M, Ikegame K, Ogawa H, Aozasa K, Kawase I, Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer, 100: 297-303, 2002.